Naveen S Vasudev

9PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 08, 2026
4-weekly avelumab plus axitinib in patients with metastatic renal cell carcinoma.

|May 09, 2025
Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.

Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez

|May 07, 2025
A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study.

Álvaro Pinto-Marín, Lucía Trilla-Fuertes, Jesús Miranda Poma

|Nov 20, 2024
Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.

Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez

|Nov 06, 2023
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

Naveen S Vasudev, Gemma Ainsworth, Sarah Brown

|Feb 23, 2023
Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma.

Naveen S Vasudev, Ghislaine Scelo, Kate I Glennon

Pageof 2

Frequent Collaborators

3 joint publications

Rosamonde E Banks

2 joint publications

Will Ince

2 joint publications

Omi Parikh

2 joint publications

Poulam Patel